Skip to main content

About Genvor

Pioneering the futureof plant health

Genvor develops advanced peptide solutions to boost yields, cut chemical use, and secure a sustainable food future.

The Genvor Origin

Built to Rethink Agriculture

Agriculture was facing a crisis. Chemical crop protection – the backbone of modern farming – was falling short. Pests were developing resistance faster than new products could be discovered. Regulatory agencies were banning proven chemicals. Consumers were demanding residue-free food. The industry needed a breakthrough, but traditional R&D was too slow and costly.

Dr. Jesse Jaynes and Dr. Clayton Yates, leading experts in therapeutic peptides, saw an opportunity others missed. If peptides could revolutionize human medicine by targeting diseases with precision and safety, why couldn't they transform agriculture? What if nature's own mechanisms could be engineered to enhance crop performance more effectively than synthetic chemicals – delivering superior yields, stress tolerance, and nutrient optimization without the resistance, residues, or regulatory hurdles?

Agriculture needed solutions optimized for peak commercial performance, not evolutionary survival. So, in 2017 they founded Genvor with a bold vision: engineer peptides that optimize agricultural outcomes with biological safety, using AI to accelerate discovery beyond what traditional R&D could achieve alone.

Our Leadership Team

Loading...

Milestones in Our Journey

Today, Genvor partners with Tier-1 agricultural leaders and leverages a capital-efficient licensing model to bring its solutions to growers worldwide. Our peptide innovations are not just scientific advances—they’re real-world tools to meet the challenges of climate change, food security, and population growth.

2025 (Expected)
Launch of first corn AMP trait for commercial licensing.
2024
Launch of first corn AMP trait for commercial licensing.
2024
Awarded Bayer’s Golden Ticket, gaining access to lab space, mentorship, and commercialization resources.
2024
Chad Pawlak appointed CEO and elected to Board of Directors.
2023
Genvor lists on OTC:QB under symbol GNVR.
2021
Second U.S. patent expands peptide applications for transgenic crops.
2018
Genvor founded; entered CRADA with USDA; patented transgenic corn with peptide AGM182.
1998
The synthetic antimicrobial peptide D4E1, developed by Dr. Jaynes in collaboration with research partners, is made publicly available as a biological control tool.
1984
Dr. Jaynes develops a comprehensive phenotype system encompassing all amino acids—laying the groundwork for a proprietary design platform that continues to evolve today.
1978
The foundation of our technology traces back more than four decades to groundbreaking academic research and early peptide development in agriculture.

Let’s Grow the Future Together

Genvor is already in talks with 6+ top-tier ag industry leaders—our licensing-first model is built for real-world deployment and long-term success.

Interested in partnering? Let’s talk.

Email: licensing@genvor.com
Phone: (715)-903-6473